2022 Rome Action Plan on Paediatric HIV & TB
CHAI commits to:
137. Enable access to affordable commodities through increasing pricing transparency especially of supply chain markups, improving inclusiveness of global access pricing across countries, and exploring improved distribution options to minimize price variability and excess costs.
138. Facilitate timely infant diagnosis and VL monitoring through prioritizing point-of-care solutions and integrated diagnostic networks with efficient sample referral and data management systems.
139. Accelerate pediatric case-finding through scaling proven testing strategies, expanding targeted testing and innovation in facility and community settings, and optimizing use of diagnostic technologies such as POC EID/VL and HIVST.
All partners commit to:
163. Address inequities by tackling the stigma and discrimination in communities, schools, and healthcare settings that prevent children living with HIV from accessing testing and treatment.
164. Increase literacy about CD4 testing and viral load and promote a client-centred approach to support expansion of access to viral load for pregnant and breastfeeding women and children on treatment, including at the point-of-care.
165. Review and assess emerging co-infections for immunocompromised infants and children, including those with advanced HIV disease, such as severe bacterial infections, fungal infections, and others for country consideration and implementation.
166. Engage affected communities for input and guidance on investment and programmatic priorities, provide support to in-country civil society organizations to engage in advocacy and demand creation for new tools, and ensure data is publicly available to support communities and civil society to monitor progress regarding uptake and implementation of essential diagnostic tools.
CHAI commits to:
309. Support product development and introduction of paediatric ABC/3TC/DTG (pALD), paediatric darunavir/ritonavir (pDRV/r), and paediatric TAF (pTAF) once regulatory approvals are received.
310. Scale implementation of the WHO recommended STOP-AIDS toolkit for children living with HIV to identify more children in need and provide a comprehensive package of care for children to prevent, diagnose, and treat drivers of morbidity and mortality.
311. Support adoption of best practices for expanding and sustaining uptake of optimal ARVs for children (e.g., granular monitoring, peer support etc.) and innovate to improve continuity in care (e.g., disclosure, mental health).
312. Engage in market shaping activities to accelerate access to optimal generic paediatric treatment products, including long-acting medications and next generation delivery methods.